VEGFA and eye disorder: Conversely, even though serum levels of VEGF are increased in patients with DR, they are not predictive of eye disease progression; however, the evidence that circulating levels of VEGF are significantly reduced in DR patients after intravitreal administration of the anti-VEGF aflibercept suggests a potential utility of dosing VEGF in plasma to monitor response to therapy [65].